{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:55:18Z","timestamp":1781715318070,"version":"3.54.5"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The 2-benzylbenzimidazole class of synthetic opioids\u2014more commonly referred to as the \u201cnitazenes\u201d\u2014are the latest of several classes of novel psychoactive substances to predominate the illicit drug market. Following the class-wide scheduling of fentanyl analogs and fentanyl-related substances in 2018, forensic toxicology laboratories in the United States began to see a proliferation of these novel synthetic opioids in casework initially stemming from the emergence of isotonitazene in 2019. Nitazenes are structurally distinct from fentanyl but share similar pharmacologic and toxicologic activity as mu-opioid receptor agonists with varying degrees of potency. In this study, we report the emergence and subsequent prevalence of the nitazenes in postmortem casework in the State of Maryland between May 2024 and August 2025. Analysis was completed utilizing a mixed-mode cationic exchange solid-phase extraction protocol and detection by ultra-performance liquid chromatography-triple quadrupole mass spectrometry. Four hundred and thirty postmortem cases were analyzed, with 3% of cases positive for one or more nitazenes. The most prevalent nitazenes detected were metonitazene (62% of positive cases), N-desethyl protonitazene (31% of positive cases), and N-pyrrolidino protonitazene (31% of positive cases). Only one case involved nitazenes as the sole substance of toxicologic significance; in all other cases, they were never the only drug detected and were frequently co-detected alongside fentanyl (85% of cases), followed by quinine (77% of cases), despropionyl fentanyl (69% of cases), cocaine\/benzoylecgonine (62% of cases), and para-fluorofentanyl (54% of cases). Given the ever-changing landscape of novel psychoactive substances, the potency and increasing prevalence of these synthetic opioids raise significant concerns and underscore the need for ongoing surveillance, advancements in analytical techniques, and targeted public health interventions to mitigate their impact on mortality trends.<\/jats:p>","DOI":"10.1093\/jat\/bkag031","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:46:19Z","timestamp":1779882379000},"source":"Crossref","is-referenced-by-count":0,"title":["Determination of nitazenes in postmortem casework and their prevalence in the State of Maryland"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-420X","authenticated-orcid":false,"given":"Michael","family":"Fagiola","sequence":"first","affiliation":[{"name":"State of Maryland Office of the Chief Medical Examiner , Baltimore, MD 21223"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Phipps","sequence":"additional","affiliation":[{"name":"State of Maryland Office of the Chief Medical Examiner , Baltimore, MD 21223"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026061711573096600_bkag031-B1","doi-asserted-by":"publisher","first-page":"CD010794","DOI":"10.1002\/14651858.CD010794.pub2","article-title":"Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews","volume":"2015","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026061711573096600_bkag031-B2","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1001\/jama.2012.14282","article-title":"Rethinking opioid prescribing to protect patient safety and public health","volume":"308","author":"Alexander","year":"2012","journal-title":"JAMA"},{"key":"2026061711573096600_bkag031-B3","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"2026061711573096600_bkag031-B4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/030006058301100206","article-title":"Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough","volume":"11","author":"Matthys","year":"1983","journal-title":"J Int Med Res"},{"key":"2026061711573096600_bkag031-B5","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.cgh.2017.05.014","article-title":"Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits","volume":"15","author":"Camilleri","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061711573096600_bkag031-B6","doi-asserted-by":"crossref","DOI":"10.23970\/AHRQEPCCER232","volume-title":"Interventions for Breathlessness in Patients with Advanced Cancer","author":"Dy","year":"2020"},{"key":"2026061711573096600_bkag031-B7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s13311-021-01019-4","article-title":"Restless legs syndrome: contemporary diagnosis and treatment","volume":"18","author":"Gossard","year":"2021","journal-title":"Neurotherapeutics"},{"key":"2026061711573096600_bkag031-B8","first-page":"227","article-title":"Non-medical prescription opioid use and prescription opioid use disorder: a review","volume":"88","author":"Tetrault","year":"2015","journal-title":"Yale J Biol Med"},{"key":"2026061711573096600_bkag031-B9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/00008480-200304000-00013","article-title":"The resurgence and abuse of heroin by children in the United States","volume":"15","author":"Tarabar","year":"2003","journal-title":"Curr Opin Pediatr"},{"key":"2026061711573096600_bkag031-B10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry"},{"key":"2026061711573096600_bkag031-B11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/dta.2738","article-title":"Report on a novel emerging class of highly potent benzimidazole NPS opioids: chemical and in vitro functional characterization of isotonitazene","volume":"12","author":"Blanckaert","year":"2020","journal-title":"Drug Test Anal"},{"key":"2026061711573096600_bkag031-B12","author":"CFSRE","year":"2019"},{"key":"2026061711573096600_bkag031-B13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026061711573096600_bkag031-B14","author":"United States Drug Enforcement Administration. Drug Scheduling"},{"key":"2026061711573096600_bkag031-B15","doi-asserted-by":"publisher","first-page":"111775","DOI":"10.1016\/j.forsciint.2023.111775","article-title":"Non-fentanyl new synthetic opioids - an update","volume":"349","author":"Zawilska","year":"2023","journal-title":"Forensic Sci Int"},{"key":"2026061711573096600_bkag031-B16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jat\/bkae066","article-title":"Assessment of \u03949-THC and \u03949-THCCOOH bias, precision, and ionization suppression\/enhancement between solid tissue homogenate and supernatant by LC-MS-MS","volume":"48","author":"Fagiola","year":"2024","journal-title":"J Anal Toxicol"},{"key":"2026061711573096600_bkag031-B17","author":"AAFS Standards Board","year":"2019"},{"key":"2026061711573096600_bkag031-B18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jat\/bkab117","article-title":"A forward-thinking approach to addressing the new synthetic opioid 2-benzylbenzimidazole nitazene analogs by liquid chromatography-tandem quadrupole mass spectrometry (LC-QQQ-MS)","volume":"46","author":"Walton","year":"2022","journal-title":"J Anal Toxicol"},{"key":"2026061711573096600_bkag031-B19","doi-asserted-by":"publisher","first-page":"100605","DOI":"10.1016\/j.forc.2024.100605","article-title":"Structural characterization of nitazene analogs using electron ionization-mass spectrometry (EI-MS)","volume":"40","author":"Hardwick","year":"2024","journal-title":"Forensic Chem. Published Online August"},{"key":"2026061711573096600_bkag031-B20","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1111\/1556-4029.70084","article-title":"Development and validation of a combined selected ion monitoring-scan GC-EI-MS method for nitazene analogs","volume":"70","author":"Phelps","year":"2025","journal-title":"J Forensic Sci"},{"key":"2026061711573096600_bkag031-B21","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1002\/dta.3921","article-title":"Structural characterization of nitazene analogs using electrospray ionization-tandem mass spectrometry (ESI-MS\/MS)","volume":"17","author":"Hardwick","year":"2025","journal-title":"Drug Test Anal"},{"key":"2026061711573096600_bkag031-B22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/15563650.2025.2504133","article-title":"Nitazenes: review of comparative pharmacology and antagonist action","volume":"63","author":"Stangeland","year":"2025","journal-title":"Clin Toxicol (Phila)"},{"key":"2026061711573096600_bkag031-B23","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s00204-024-03774-7","article-title":"In vitro structure-activity relationships and forensic case series of emerging 2-benzylbenzimidazole \u201cnitazene\u201d opioids","volume":"98","author":"De Vrieze","year":"2024","journal-title":"Arch Toxicol"},{"key":"2026061711573096600_bkag031-B24","doi-asserted-by":"publisher","first-page":"107503","DOI":"10.1016\/j.phrs.2024.107503","article-title":"Characterization of novel nitazene recreational drugs: insights into their risk potential from in vitro \u00b5-opioid receptor assays and in vivo behavioral studies in mice","volume":"210","author":"Vandeputte","year":"2024","journal-title":"Pharmacol Res"},{"key":"2026061711573096600_bkag031-B25","doi-asserted-by":"publisher","first-page":"1434573","DOI":"10.3389\/fphar.2024.1434573","article-title":"Metabolic characterization of the new benzimidazole synthetic opioids - nitazenes","volume":"15","author":"Jadhav","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026061711573096600_bkag031-B26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jat\/bkad062","article-title":"Validation of an analytical method for quantitation of metonitazene and isotonitazene in plasma, blood, urine, liver and brain and application to authentic postmortem casework in New York City","volume":"47","author":"Pardi","year":"2023","journal-title":"J Anal Toxicol"},{"key":"2026061711573096600_bkag031-B27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jat\/bkaf042","article-title":"Protonitazene metabolite variability in post-mortem casework","volume":"49","author":"Wood","year":"2025","journal-title":"J Anal Toxicol"},{"key":"2026061711573096600_bkag031-B28","author":"Taruvinga","year":"2024"},{"key":"2026061711573096600_bkag031-B29","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/1556-4029.70052","article-title":"Evaluation of enzyme-linked immunosorbent assay screening kits for the detection of nitazene analogs","volume":"70","author":"Pacana","year":"2025","journal-title":"J Forensic Sci."},{"key":"2026061711573096600_bkag031-B30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/jat\/bky050","article-title":"Screening of novel psychoactive substances in postmortem matrices by liquid chromatography-tandem mass spectrometry (LC-MS-MS)","volume":"42","author":"Fagiola","year":"2018","journal-title":"J Anal Toxicol"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkag031\/68434568\/bkag031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/6\/bkag031\/68434568\/bkag031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/6\/bkag031\/68434568\/bkag031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:57:36Z","timestamp":1781711856000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/doi\/10.1093\/jat\/bkag031\/8698335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkag031","relation":{},"ISSN":["1945-2403"],"issn-type":[{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,29]]},"article-number":"bkag031"}}